Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Oklahoma judge to rule...

    Oklahoma judge to rule in opioid lawsuit against JnJ

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-08-24T09:10:30+05:30  |  Updated On 16 Aug 2021 5:37 PM IST

    Lawyers for the state called JnJ an opioid "kingpin" and contended its marketing efforts created a public nuisance in the form of the opioid crisis as doctors over-prescribed the drugs, leading to a surge in overdose deaths in Oklahoma.


    U.S: An Oklahoma judge will rule on Monday on whether Johnson & Johnson (JnJ) should be held liable in a lawsuit by the state's attorney general who argues the drugmaker should be forced to pay $17 billion for fueling the opioid epidemic.


    Judge Thad Balkman in Norman, Oklahoma, will deliver his decision from the bench after presiding over the first trial to result from thousands of lawsuits by state and local governments against opioid manufacturers and distributors, the court said.


    Opioids were involved in almost 400,000 overdose deaths from 1999 to 2017, according to the U.S. Centers for Disease Control and Prevention. Since 2000, some 6,000 Oklahomans have died from opioid overdoses, according to the state's lawyers.


    During a seven-week, a non-jury trial that began in May, Oklahoma Attorney General Mike Hunter sought to establish that J&J carried out a years-long marketing campaign that minimized the addictive painkillers' risks while promoting their benefits.


    Lawyers for the state called J&J an opioid "kingpin" and contended its marketing efforts created a public nuisance in the form of the opioid crisis as doctors over-prescribed the drugs, leading to a surge in overdose deaths in Oklahoma.


    JnJ denied wrongdoing. It contends its painkillers, Duragesic and Nucynta, were a tiny fraction of all opioids prescribed in Oklahoma. It also said its marketing claims had scientific support.


    Lawyers for New Jersey-based JnJ also contend in court papers that the state's case rests on "radical theories" disconnected from more than a century of court cases interpreting the state's public nuisance law.


    JnJ had no comment on Wednesday.


    The case is being closely watched by plaintiffs in other opioid lawsuits, particularly in around 2,000 cases pending before a federal judge in Ohio who has been pushing for a settlement ahead of an October trial.


    OxyContin maker Purdue Pharma LP and Teva Pharmaceutical Industries Ltd were originally also defendants in the case. Purdue reached a $270 million settlement with Oklahoma in March and Teva settled for $85 million in May. Both deny wrongdoing.


    By Nate Raymond


    Read Also: J&J passes asbestos test, allowed to make baby powder in India

    Attorney GeneralDuragesicJnJJohnson & JohnsonjudgekingpinMike HunterNate RaymondNucyntaOklahomaopioid crisisopioid lawsuitOxyContinpharmapharma companypharma newsPurdue Pharmaradical theoriesTeva Pharmaceutical IndustriesThad Balkman
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok